Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 75

1.

Corrigendum: Why Be One Protein When You Can Affect Many? The Multiple Roles of YB-1 in Lung Cancer and Mesothelioma.

Johnson TG, Schelch K, Mehta S, Burgess A, Reid G.

Front Cell Dev Biol. 2019 Nov 22;7:293. doi: 10.3389/fcell.2019.00293. eCollection 2019.

PMID:
31807495
2.

Phenotypic screen for oxygen consumption rate identifies an anti-cancer naphthoquinone that induces mitochondrial oxidative stress.

Byrne FL, Olzomer EM, Marriott GR, Quek LE, Katen A, Su J, Nelson ME, Hart-Smith G, Larance M, Sebesfi VF, Cuff J, Martyn GE, Childress E, Alexopoulos SJ, Poon IK, Faux MC, Burgess AW, Reid G, McCarroll JA, Santos WL, Quinlan KG, Turner N, Fazakerley DJ, Kumar N, Hoehn KL.

Redox Biol. 2019 Nov 5;28:101374. doi: 10.1016/j.redox.2019.101374. [Epub ahead of print]

3.

Why Be One Protein When You Can Affect Many? The Multiple Roles of YB-1 in Lung Cancer and Mesothelioma.

Johnson TG, Schelch K, Mehta S, Burgess A, Reid G.

Front Cell Dev Biol. 2019 Oct 1;7:221. doi: 10.3389/fcell.2019.00221. eCollection 2019. Review. Erratum in: Front Cell Dev Biol. 2019 Nov 22;7:293.

4.

The Δ133p53β isoform promotes an immunosuppressive environment leading to aggressive prostate cancer.

Kazantseva M, Mehta S, Eiholzer RA, Gimenez G, Bowie S, Campbell H, Reily-Bell AL, Roth I, Ray S, Drummond CJ, Reid G, Joruiz SM, Wiles A, Morrin HR, Reader KL, Hung NA, Baird MA, Slatter TL, Braithwaite AW.

Cell Death Dis. 2019 Aug 20;10(9):631. doi: 10.1038/s41419-019-1861-1.

5.

Transcriptional suppression of the miR-15/16 family by c-Myc in malignant pleural mesothelioma.

Williams M, Cheng YY, Kirschner MB, Sarun KH, Schelch K, Winata P, McCaughan B, Kao S, Van Zandwijk N, Reid G.

Oncotarget. 2019 Jun 25;10(41):4125-4138. doi: 10.18632/oncotarget.27010. eCollection 2019 Jun 25.

6.

High BIN1 expression has a favorable prognosis in malignant pleural mesothelioma and is associated with tumor infiltrating lymphocytes.

Ahmadzada T, Lee K, Clarke C, Cooper WA, Linton A, McCaughan B, Asher R, Clarke S, Reid G, Kao S.

Lung Cancer. 2019 Apr;130:35-41. doi: 10.1016/j.lungcan.2019.02.005. Epub 2019 Feb 7.

PMID:
30885349
7.

When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?

Baird AM, Easty D, Jarzabek M, Shiels L, Soltermann A, Klebe S, Raeppel S, MacDonagh L, Wu C, Griggs K, Kirschner MB, Stanfill B, Nonaka D, Goparaju CM, Murer B, Fennell DA, O'Donnell DM, Barr MP, Mutti L, Reid G, Finn S, Cuffe S, Pass HI, Opitz I, Byrne AT, O'Byrne KJ, Gray SG.

Front Endocrinol (Lausanne). 2019 Feb 26;10:89. doi: 10.3389/fendo.2019.00089. eCollection 2019.

8.

Integrative Molecular Characterization of Malignant Pleural Mesothelioma.

Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, Stewart C, Heiman D, Tarpey P, Danilova L, Drill E, Gibb EA, Bowlby R, Kanchi R, Osmanbeyoglu HU, Sekido Y, Takeshita J, Newton Y, Graim K, Gupta M, Gay CM, Diao L, Gibbs DL, Thorsson V, Iype L, Kantheti H, Severson DT, Ravegnini G, Desmeules P, Jungbluth AA, Travis WD, Dacic S, Chirieac LR, Galateau-Sallé F, Fujimoto J, Husain AN, Silveira HC, Rusch VW, Rintoul RC, Pass H, Kindler H, Zauderer MG, Kwiatkowski DJ, Bueno R, Tsao AS, Creaney J, Lichtenberg T, Leraas K, Bowen J; TCGA Research Network, Felau I, Zenklusen JC, Akbani R, Cherniack AD, Byers LA, Noble MS, Fletcher JA, Robertson AG, Shen R, Aburatani H, Robinson BW, Campbell P, Ladanyi M.

Cancer Discov. 2018 Dec;8(12):1548-1565. doi: 10.1158/2159-8290.CD-18-0804. Epub 2018 Oct 15.

9.

BAMLET kills chemotherapy-resistant mesothelioma cells, holding oleic acid in an activated cytotoxic state.

Rath EM, Cheng YY, Pinese M, Sarun KH, Hudson AL, Weir C, Wang YD, Håkansson AP, Howell VM, Liu GJ, Reid G, Knott RB, Duff AP, Church WB.

PLoS One. 2018 Aug 29;13(8):e0203003. doi: 10.1371/journal.pone.0203003. eCollection 2018.

10.

An Update on Predictive Biomarkers for Treatment Selection in Non-Small Cell Lung Cancer.

Ahmadzada T, Kao S, Reid G, Boyer M, Mahar A, Cooper WA.

J Clin Med. 2018 Jun 15;7(6). pii: E153. doi: 10.3390/jcm7060153. Review.

11.

A data-driven, knowledge-based approach to biomarker discovery: application to circulating microRNA markers of colorectal cancer prognosis.

Vafaee F, Diakos C, Kirschner MB, Reid G, Michael MZ, Horvath LG, Alinejad-Rokny H, Cheng ZJ, Kuncic Z, Clarke S.

NPJ Syst Biol Appl. 2018 Jun 1;4:20. doi: 10.1038/s41540-018-0056-1. eCollection 2018.

12.

Biomarkers in malignant pleural mesothelioma: current status and future directions.

Ahmadzada T, Reid G, Kao S.

J Thorac Dis. 2018 Apr;10(Suppl 9):S1003-S1007. doi: 10.21037/jtd.2018.04.31. No abstract available.

13.

FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal.

Schelch K, Wagner C, Hager S, Pirker C, Siess K, Lang E, Lin R, Kirschner MB, Mohr T, Brcic L, Marian B, Holzmann K, Grasl-Kraupp B, Krupitza G, Laszlo V, Klikovits T, Dome B, Hegedus B, Garay T, Reid G, van Zandwijk N, Klepetko W, Berger W, Grusch M, Hoda MA.

Carcinogenesis. 2018 Apr 5;39(4):534-545. doi: 10.1093/carcin/bgy018.

PMID:
29635378
14.

Response to "An innovative mesothelioma treatment based on mir-16 mimic loaded EGFR targeted minicells (TargomiRs)".

van Zandwijk N, McDiarmid J, Brahmbhatt H, Reid G.

Transl Lung Cancer Res. 2018 Feb;7(Suppl 1):S60-S61. doi: 10.21037/tlcr.2018.01.11. No abstract available.

15.

SFRP Tumour Suppressor Genes Are Potential Plasma-Based Epigenetic Biomarkers for Malignant Pleural Mesothelioma.

Cheng YY, Mok E, Tan S, Leygo C, McLaughlin C, George AM, Reid G.

Dis Markers. 2017;2017:2536187. doi: 10.1155/2017/2536187. Epub 2017 Dec 13.

16.

Fundamentals of siRNA and miRNA therapeutics and a review of targeted nanoparticle delivery systems in breast cancer.

Ahmadzada T, Reid G, McKenzie DR.

Biophys Rev. 2018 Feb;10(1):69-86. doi: 10.1007/s12551-017-0392-1. Epub 2018 Jan 11. Review.

17.

The analysis of novel microRNA mimic sequences in cancer cells reveals lack of specificity in stem-loop RT-qPCR-based microRNA detection.

Winata P, Williams M, McGowan E, Nassif N, van Zandwijk N, Reid G.

BMC Res Notes. 2017 Nov 17;10(1):600. doi: 10.1186/s13104-017-2930-0.

18.

Dysregulated Expression of the MicroRNA miR-137 and Its Target YBX1 Contribute to the Invasive Characteristics of Malignant Pleural Mesothelioma.

Johnson TG, Schelch K, Cheng YY, Williams M, Sarun KH, Kirschner MB, Kao S, Linton A, Klebe S, McCaughan BC, Lin RCY, Pirker C, Berger W, Lasham A, van Zandwijk N, Reid G.

J Thorac Oncol. 2018 Feb;13(2):258-272. doi: 10.1016/j.jtho.2017.10.016. Epub 2017 Nov 4.

19.

A link between the fibroblast growth factor axis and the miR-16 family reveals potential new treatment combinations in mesothelioma.

Schelch K, Kirschner MB, Williams M, Cheng YY, van Zandwijk N, Grusch M, Reid G.

Mol Oncol. 2018 Jan;12(1):58-73. doi: 10.1002/1878-0261.12150. Epub 2017 Nov 18.

20.

Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.

van Zandwijk N, Pavlakis N, Kao SC, Linton A, Boyer MJ, Clarke S, Huynh Y, Chrzanowska A, Fulham MJ, Bailey DL, Cooper WA, Kritharides L, Ridley L, Pattison ST, MacDiarmid J, Brahmbhatt H, Reid G.

Lancet Oncol. 2017 Oct;18(10):1386-1396. doi: 10.1016/S1470-2045(17)30621-6. Epub 2017 Sep 1.

PMID:
28870611

Supplemental Content

Loading ...
Support Center